SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,460 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,460 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $19.62, for a total value of $67,885.20. Following the transaction, the senior vice president directly owned 228,436 shares of the company’s stock, valued at approximately $4,481,914.32. This represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

SiBone Stock Up 2.2%

SIBN stock traded up $0.43 during trading on Tuesday, hitting $20.40. 412,471 shares of the company’s stock were exchanged, compared to its average volume of 464,090. The business has a 50-day moving average price of $18.49 and a two-hundred day moving average price of $17.01. The stock has a market capitalization of $885.18 million, a price-to-earnings ratio of -40.00 and a beta of 0.69. SiBone has a 52-week low of $12.49 and a 52-week high of $21.07. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. The company had revenue of $48.66 million for the quarter, compared to analysts’ expectations of $46.67 million. As a group, equities research analysts expect that SiBone will post -0.78 EPS for the current year.

Institutional Trading of SiBone

A number of institutional investors have recently modified their holdings of SIBN. Harbor Capital Advisors Inc. boosted its holdings in SiBone by 7.7% during the second quarter. Harbor Capital Advisors Inc. now owns 573,705 shares of the company’s stock worth $10,797,000 after buying an additional 40,993 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of SiBone during the 3rd quarter valued at approximately $3,297,000. Palumbo Wealth Management LLC purchased a new stake in shares of SiBone during the 2nd quarter worth approximately $577,000. Goldman Sachs Group Inc. grew its holdings in shares of SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after acquiring an additional 83,919 shares during the period. Finally, Divisadero Street Capital Management LP increased its stake in SiBone by 17.8% in the 2nd quarter. Divisadero Street Capital Management LP now owns 339,791 shares of the company’s stock valued at $6,395,000 after purchasing an additional 51,363 shares in the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SIBN. Needham & Company LLC raised their target price on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Canaccord Genuity Group lifted their price objective on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Morgan Stanley upped their target price on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Truist Financial raised their price target on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.